Forest Memantine Plans Include Expanded Mild Alzheimer’s Indication
Executive Summary
Forest plans to expand the indication of its Alzheimer's drug Namenda (memantine) to include patients with mild dementia if study results expected at the end of the year are positive
You may also be interested in...
Forest Namenda Clears FDA; Alzheimer Drug Shipments To Begin In December
Forest is planning a slow roll-out of Namenda (memantine) after a faster-than-expected approval of the Alzheimer's agent
Forest Memantine Shows Small But Consistent Effect In Alzheimer’s – Cmte.
Forest memantine (Namenda) has a small but consistent effect in patients with moderate to severe Alzheimer's dementia, FDA's Peripheral & Central Nervous System Drugs Advisory Committee concluded Sept. 25
Forest Lexapro Strategy Changes: Reps Encouraging Switches From Celexa
Forest is restructuring its sales representative compensation program to encourage switches from the company's antidepressant Celexa to the follow-on selective serotonin reuptake inhibitor Lexapro